New data shows high sensitivity and specificity for the blood-based biopsy test in patients at elevated risk for the disease.
ClearNote Health will present performance data for its Avantect Pancreatic Cancer Test at the Digestive Disease Week 2026 conference in Chicago, May 2 to 5. According to the company, the test delivers detection sensitivity of 82.6% and specificity of 97.5% for patients at elevated risk of the disease.
The Avantect test is a multi-analyte, multiomic liquid biopsy designed to identify signals for pancreatic cancer by combining 5hmC-based epigenomic profiling with other genomic and molecular features. The company uses machine learning algorithms to analyze these signals to provide early detection performance.
“Our multi-analyte, multiomic liquid biopsy test is designed to supplement and enhance conventional approaches and reveal biologically meaningful signals for pancreatic cancer detection,” says Samuel Levy, PhD, chief science officer at ClearNote Health, in a release.
The test is intended for patients with known genetic predispositions, a family history of pancreatic cancer, or individuals age 50 and older who are newly diagnosed with type 2 diabetes.
“Gastroenterologists are uniquely positioned to identify patients at elevated risk, including those with new-onset diabetes, family history, smoking, or inherited predisposition, and to help guide appropriate surveillance discussions,” says Jeffrey Venstrom, MD, chief medical officer at ClearNote Health, in a release. “Our Avantect Pancreatic Cancer Test is designed to provide additional insight alongside other clinical findings when earlier detection matters most.”
Scheduled Presentations
The company’s data will be featured in two sessions during the conference:
Plenary Presentation: Anna Bergamaschi, PhD, will present “Evaluation of a Blood-Based Molecular Biomarker Test for the Surveillance of Individuals at High Risk for Pancreatic Cancer” during the ASGE Presidential Plenary on May 3.
Poster Presentation: Randall E Brand, MD, professor of medicine at the University of Pittsburgh, will present poster #773 on the same study on May 4.
Ongoing Clinical Studies
The next-generation test is currently being utilized in the Surveillance of pAncreatic health aFter diabEtes Diagnosis (SAFE-D) study. Led by the National Health Service in the UK, the project is one of the largest evaluating pancreatic cancer detection in individuals with new-onset diabetes.
The test is also part of the international Pancreatic Cancer Early Detection Consortium. This global multi-center effort focuses on advancing risk-stratified screening and earlier diagnosis for individuals with genetic or familial risk factors.
